Cardiac Tissue Engineering Global Market Report 2025

The cardiac tissue engineering market size has grown rapidly in recent years. It will grow from $0.67 billion in 2024 to $0.81 billion in 2025 at a compound annual growth rate (CAGR) of 19.7%. The growth during the historic period was driven by organ donor shortages, the increasing prevalence of cardiovascular diseases, innovations in biomaterials, rising investment in regenerative medicine, demand for personalized medicine, advancements in bioreactor systems, increasing government funding for biomedical research, and a growing focus on minimally invasive therapies.

The cardiac tissue engineering market size is expected to see rapid growth in the next few years. It will grow to $1.64 billion in 2029 at a compound annual growth rate (CAGR) of 19.4%. The projected growth in the forecast period is driven by increasing demand for personalized cardiac therapies, a rising focus on bioengineered heart tissues, the expansion of regenerative medicine applications, growing collaborations between biotech firms and academia, increased investment in preclinical testing platforms, and the rising prevalence of chronic heart diseases. Key trends include the integration of AI in tissue engineering, advancements in nanotechnology-based scaffolds, the development of biodegradable hydrogels, progress in 3D bioprinting precision, the use of bioreactors for tissue maturation, and gene editing for cardiac cell enhancement.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the cardiac tissue engineering market. Cardiac tissue engineering is an interdisciplinary field dedicated to creating biological or bioartificial constructs to repair, regenerate, or replace damaged heart tissue. The rise in cardiovascular diseases is largely attributed to unhealthy lifestyle choices, including poor diet, physical inactivity, smoking, and rising obesity and diabetes rates. Cardiac tissue engineering addresses cardiovascular diseases by utilizing biomaterials, cell-based therapies, and bioengineered tissues to repair or regenerate damaged heart muscle and restore cardiac function. For example, in May 2023, the Centers for Disease Control and Prevention, a US-based governmental organization, reported that the prevalence of coronary heart disease among female adults aged 18 and over slightly increased to 3.7% in 2023 from 3.6% in 2022. Consequently, the rising incidence of cardiovascular diseases is fueling the expansion of the cardiac tissue engineering market.

Leading companies in the cardiac tissue engineering market are focusing on technological advancements, such as 3D-engineered muscle tissues, to improve the accuracy and efficiency of drug discovery for cardiovascular disease treatments. 3D-engineered muscle tissues are bioengineered constructs that mimic the structural and functional properties of human muscle, primarily used for drug testing and disease modeling. For instance, in July 2022, Curi Bio Inc., a US-based biotechnology company, introduced the Mantarray platform for analyzing contractility in human-relevant 3D heart and skeletal engineered muscle tissue (EMT). This platform leverages advanced tissue culture techniques to generate highly functional muscle tissues that replicate the mechanical properties and behavior of natural muscle, providing a more precise model for drug testing. The technology enhances the development of therapeutic solutions by enabling researchers to study muscle contraction, responses to stimuli, and disease modeling at a cellular level.

In April 2024, Valo Health LLC, a US-based technology company, acquired TARA Biosystems Inc. for an undisclosed amount. Through this acquisition, Valo Health aims to leverage TARA's proprietary human cardiac disease platform to advance the discovery of new medicines for cardiovascular diseases. TARA Biosystems Inc. is a US-based company specializing in the development of 3D-engineered cardiac tissue models for drug discovery and disease modeling.

Major players in the cardiac tissue engineering market are Biotronik SE & Co. KG, Terumo Corporation, Artivion Inc., Tissue Regenix Group plc, PromoCell GmbH, Xeltis AG, Carmat S.A., Bioheart Inc., Prellis Biologics Inc., Cytograft Tissue Engineering Inc., Avery Therapeutics Inc., Vascudyne Inc., Auto Tissue Berlin GmbH, CorMatrix Cardiovascular Inc., Humacyte Inc., BioCardia Inc., Osiris Therapeutics Inc., StemCells Inc., ViroMed Co. Ltd., Cardio3 Biosciences.

North America was the largest region in the cardiac tissue engineering market in 2024. The regions covered in cardiac tissue engineering report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cardiac tissue engineering market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cardiac tissue engineering involves advanced biomedical techniques to develop functional heart tissue for repairing or regenerating damaged heart muscles. This field integrates cells, biomaterials, and bioactive factors to create engineered tissues that restore cardiac function and support heart disease treatment.

The primary products in cardiac tissue engineering include heart valves and vascular grafts. Heart valves regulate blood flow within the heart, ensuring proper circulation. The key materials used are stem cells and scaffolds. Applications range from myocardial infarction treatment and heart valve repair or replacement to congenital heart disease management and more. These technologies are utilized by hospitals and clinics, academic and research institutes, and other healthcare providers.

The cardiac tissue engineering market research report is one of a series of new reports that provides cardiac tissue engineering market statistics, including cardiac tissue engineering industry global market size, regional shares, competitors with a cardiac tissue engineering market share, detailed cardiac tissue engineering market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac tissue engineering industry. This cardiac tissue engineering market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cardiac tissue engineering market consists of revenues earned by entities by providing services such as the development of stem cell therapy and regeneration services, tissue engineering consultation and research services, and bioreactor and biomanufacturing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiac tissue engineering market includes sales of bioengineered cardiac tissues, biomaterials, cardiac tissue constructs, tissue scaffolds, bioactive molecules, and bioreactors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.